Vinorelbine and Gemcitabine as Second- or Third-Line Therapy for Malignant Pleural Mesothelioma

OBJECTIVES: Pemetrexed-cisplatin is the only FDA-approved regimen for malignant pleural mesothelioma (MPM), and the impact on survival is modest. No drugs have been shown to improve survival as second-line therapy, yet vinorelbine and gemcitabine are prescribed based on the results of small phase II...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lung Cancer
Asıl Yazarlar: Zauderer, Marjorie G., Kass, Samantha L., Woo, Kaitlin, Sima, Camelia S., Ginsberg, Michelle S., Krug, Lee M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4343315/
https://ncbi.nlm.nih.gov/pubmed/24690410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2014.03.006
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller